MNOV

MediciNova Inc

Add to Watchlist

Advanced Chart

1.260

+0.03(2.439%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

1.270

Open

1.230

VWAP

1.26

Vol

20.59K

Mkt Cap

61.80M

Low

1.230

Amount

25.91K

EV/EBITDA(TTM)

Total Shares

49.05M

23.76M

EV/OCF(TTM)

P/S(TTM)

MediciNova, Inc. is a biopharmaceutical company that is developing therapeutics with a primary focus on neurology, respiratory and liver diseases. The Company's development activities are focused on MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, substance dependence and addiction (methamphetamine dependence, opioid dependence and alcohol dependence), prevention of acute respiratory distress syndrome, and Long COVID, and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease and hypertriglyceridemia. Its MN-166 (ibudilast) is a first-in-class, oral, anti-inflammatory and neuroprotective agent. The FDA has granted Fast Track designations to MN-166 (ibudilast) for three separate indications: progressive MS, ALS, and methamphetamine dependence.

1 Analyst Rating

296.83% Upside

Wall Street analysts forecast MNOV stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MNOV is 5.00 USD with a low forecast of 5.00 USD and a high forecast of 5.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

1 Buy

0 Hold

0 Sell

Moderate Buy

296.83% Upside

Current: 1.260

Low

5.00

Averages

5.00

High

5.00

296.83% Upside

Current: 1.260

Low

5.00

Averages

5.00

High

5.00

B. Riley

Buy

downgrade

$6 -> $5

2025-06-17

Reason

B. Riley

Price Target

$6 -> $5

2025-06-17

downgrade

Buy

Reason

B. Riley lowered the firm's price target on MediciNova to $5 from $6 and keeps a Buy rating on the shares. The firm points out the company's current cash on hand of $37M implies a runway into 2027. It updated MediciNova's model, now exclusively focused on amyotrophic lateral sclerosis-related risk-adjusted revenue and spending.

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-04-09

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-04-09

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-03-14

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-03-14

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2025-02-21

Reason

D. Boral Capital

Jason Kolbert

Price Target

2025-02-21

Maintains

Strong Buy

Reason

D. Boral Capital

Jason Kolbert

Strong Buy

Maintains

2024-12-06

Reason

D. Boral Capital

Jason Kolbert

Price Target

2024-12-06

Maintains

Strong Buy

Reason

D. Boral Capital initiated coverage of MediciNova with a Buy rating and $9 price target. The company is retasking an old drug, Ibudilast - originally used in Japan for asthma, to treat amyotrophic lateral sclerosis, the analyst tells investors in a research note. The firm says the data in ALS shows a significant efficacy signal while the drug is known to be very safe. This combination suggests it may find broad use in ALS and, ultimately, some of the other target indications, such as multiple sclerosis, contends D. Boral.

D. Boral Capital

Jason Kolbert

Strong Buy

Initiates

2024-12-02

Reason

D. Boral Capital

Jason Kolbert

Price Target

2024-12-02

Initiates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for MediciNova Inc (MNOV.O) is -3.92, compared to its 5-year average forward P/E of -9.82. For a more detailed relative valuation and DCF analysis to assess MediciNova Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.82

Current PE

-3.92

Overvalued PE

-1.37

Undervalued PE

-18.28

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

2.29

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

9.93

Undervalued EV/EBITDA

-5.36

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

41.23

Current PS

0.00

Overvalued PS

124.23

Undervalued PS

-41.78